Table 6.
Guidelines | Patient characteristics | Treatment recommendations |
---|---|---|
JNC 8 | Patients categorised based on age, goal BP, race and patients with diabetes/CKD | Specifies drug classes to be used as first-line treatment and longer-term follow-up treatment options if BP remains uncontrolled |
ASH/ISH | Patients categorised based on BP and other factors e.g., age, race, comorbidities | Specifies drug class to be used as first-line treatment and longer-term follow-up treatment options if BP remains uncontrolled |
AHA/ACC/CDC | Patients categorised based on stage of hypertension | Suggests drug classes to be used, monitoring and follow-up options |
CHEP | Provides algorithms for diagnosis and treatment | Specifies drug classes to be used as first-line treatment and longer-term follow-up treatment options if BP remains uncontrolled |
ESH/ESC | Patients categorised based on low or high risk |
Describes steps to be taken in moving to a more intensive therapy through dose titration or adding more drugs No recommendations on drug classes or doses |
France | No algorithm provided | n/a |
NICE | Diagnosis and treatment algorithms. Treatment algorithm categorised based on age and race | Recommends drug classes to be used for initial therapy and drug combinations to be considered if BP remains uncontrolled |
Taiwan | Patients categorised based on BP and non-high risk or high risk | Specifies the number of drugs to be prescribed but not specific drug classes or doses |
China | Patients categorised based on BP and risk assessment | Specifies drug classes to be used as first-line treatment and longer-term follow-up treatment options if BP remains uncontrolled |
AHA/ACC/CDC American Hypertension Association/American College of Cardiology/Centers for Disease Control and Prevention, ASH/ISH American Society of Hypertension/International Society of Hypertension, CHEP Canadian hypertension education program, ESH/ESC European Society of Hypertension/European Society of Cardiology, JNC 8 Eighth Joint National Committee, NICE National Institute for Clinical Excellence (UK), BP blood pressure, CKD chronic kidney disease, n/a not applicable